AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00549887
Drug: Analog or Human Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescribed in accordance with usual clinical practice
Trial: NCT01316887
Drug: 125/25 mcg once-daily GSK573719/GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719/GW642444
Trial: NCT01316887
Drug: 125mcg once-daily GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719
Trial: NCT01316887
Drug: Placebo once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive
Trial: NCT01476813
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug versus comparator
Trial: NCT03987230
Drug: Sensitive Eyes® Plus Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitive Eyes® Plus Saline Solution
Trial: NCT01743521
Drug: TPV/PEG-IFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.
Trial: NCT02141958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be used to keep the study double-blind.
Trial: NCT02099136
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00664183
Drug: Vitreosolve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT04191148
Drug: LBP-EC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
Trial: NCT04191148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactated Ringers Solution for Injection dosed BID by intraurethral administration
Trial: NCT01588366
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03530462
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 monthly for 4-6 cycles depending on the response
Trial: NCT03530462
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
Trial: NCT00644111
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
Trial: NCT01841112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
Trial: NCT01628965
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Trial: NCT01438840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01438840
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Trial: NCT00025662
Drug: RFT5-SMPT-dgA
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A specific anti-interleukin-2 receptor immunotoxin
Trial: NCT00025662
Drug: Isolex system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34 selection/ T cell depletion used this system
Trial: NCT00485550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00963443
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 Sachets of 500 mg Aspirin Complex.
Trial: NCT00963443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03498586
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters
Trial: NCT01470599
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL TABLET, TWICE DAILY
Trial: NCT01470599
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL TABLETS, TWICE DAILY
Trial: NCT00004039
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004039
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02142634
Drug: Placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per day
Trial: NCT00383240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo metered dose inhaler twice a day for 26 weeks
Trial: NCT02042638
Drug: hCG 1500 IU three times a week
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02042638
Drug: Pregnyl (hCG) ampule 1500 IU/three times a week
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002796
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002796
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00136032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
Trial: NCT01339624
Drug: FENTANYL
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FENTANYL CITRATE, NASAL, 3 GAMMA/KG
Trial: NCT01339624
Drug: Ketorolac Tromethamine AND morphine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
Trial: NCT00406406
Drug: SKI-606
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002716
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002716
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02830542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Trial: NCT00695500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, 0 mg per day for 3 weeks
Trial: NCT01836016
Drug: Bufei granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
Trial: NCT02443506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
Trial: NCT01836016
Drug: conventional medicine + TCM
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
Trial: NCT04199455
Drug: Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day.
Trial: NCT04199455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day.
Trial: NCT02671318
Drug: Maintenance of the current regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
Trial: NCT03230383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for PF-06865571 for each cohort.
Trial: NCT02902653
Drug: Vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal delivery system of 10mg of dinoprostone
Trial: NCT04546022
Drug: Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00151905
Drug: 3 % hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01143545
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 g po bid
Trial: NCT01143545
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg po bid
Trial: NCT00002547
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002547
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00889837
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staccato Placebo, inhalations x 2 , 10 hours apart
Trial: NCT03304756
Drug: CAP
RxNorm normalized name: CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
Trial: NCT01542021
Drug: androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01585298
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04699097
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg tablet, 5 ml / 200 mg 30 ml suspension
Trial: NCT01590771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to sitagliptin oral tablet once daily for 24 weeks
Trial: NCT02929719
Drug: Aczone Gel 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel
Trial: NCT02929719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel
Trial: NCT03075501
Drug: Stimulant or sedative
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS+ for paired, CS0 for unpaired
Trial: NCT03075501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS- for paired, CS0 for unpaired
Trial: NCT01251822
Drug: PEG 3350 plus electrolytes
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
Trial: NCT02794025
Drug: natural saline
RxNorm normalized name: XYNASE Natural Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group also received natural saline via a micro pump,
Trial: NCT03790540
Drug: Topical Benzocaine 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzocaine 20% gel on the mucosal injection site prior to injection
Trial: NCT02189577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
Trial: NCT00155883
Drug: Taxteral
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00155883
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01262118
Drug: CP-690,550 (tasocitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
Trial: NCT02604797
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient-controlled intravenous analgesia
Trial: NCT00694135
Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
Trial: NCT00694135
Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
Trial: NCT00694135
Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
Trial: NCT01802515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
Trial: NCT04321278
Drug: Hydroxychloroquine + azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Trial: NCT01554293
Drug: PBL 1427 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBL 1427 capsules 20 mg and 150 mg, single dose
Trial: NCT03756064
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet: 400mg orally daily
Trial: NCT00056329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for three years
Trial: NCT00047541
Drug: Alcon Investigational Agent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01980524
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02413593
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT03845075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
Trial: NCT01209741
Drug: MK-0974 5Mo5C
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
Trial: NCT00935259
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg once daily for 2 weeks
Trial: NCT00935259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
Trial: NCT00904683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously (IV) every 4 weeks for 80 weeks
Trial: NCT00001677
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00829660
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
Trial: NCT02801409
Drug: General anesthesia alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
Trial: NCT02937896
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg intravenous Ketorolac.
Trial: NCT02937896
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1cc intravenous Normal Saline.
Trial: NCT02937896
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 puffs nasal Normal Saline.
Trial: NCT04515628
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT00738985
Drug: ezetimibe/simvastatin 10/20 mg + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo (sugar tablets) for up to 22 weeks.
Trial: NCT00738985
Drug: ezetimibe/simvastatin 10/20 mg + MK0524A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
Trial: NCT02411708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single two-hour infusion of placebo
Trial: NCT00409409
Drug: 300 IR grass pollen allergen extract tablet
RxNorm normalized name: orchard grass pollen extract 300 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Trial: NCT00409409
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Trial: NCT06382571
Drug: Renin-Angiotensin System Inhibitor
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00716547
Drug: ketoprofen in Diractin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg (b.i.d.)
Trial: NCT00716547
Drug: ketoprofen in Diractin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (b.i.d.)
Trial: NCT00716547
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg (b.i.d.)
Trial: NCT02970032
Drug: Real time heparin dose adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
Trial: NCT02970032
Drug: Standard heparin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be placed on heparin infusions per their surgeon's discretion.